A pharmaceutical combination comprising: (a) an alpha-isoform specific phosphatidylinositol-3- kinase inhibitor (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1- dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, (b) an mTOR inhibitor and (c) exemestane or any pharmaceutically acceptable salt thereof, particularly for use in the treatment or prevention of a proliferative disease； uses of such a combination in the preparation of a medicament for the treatment or prevention of a proliferative disease； pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a proliferative disease in a subject comprising administering to said subject a therapeutically effective amount of such a combination.
